A Study of FT 4101 in Overweight/Obese Participants With NASH
Status:
Terminated
Trial end date:
2020-01-20
Target enrollment:
Participant gender:
Summary
This Phase 1/2 study will evaluate safety, efficacy, PK, and PD of FT-4101 as a single agent
in overweight/obese subjects with NASH.
The study may be conducted in up to 2 dosing cohorts.